Incidence, Risk, and Clinical Course of New-Onset Diabetes in Long COVID: Protocol for a Systematic Review and Meta-Analysis of Cohort Studies

Overview

Journal JMIR Res Protoc

Publisher JMIR Publications

Specialty General Medicine

Date 2024 Jun 4

PMID 38833277

Authors

Ananya Sri Talanki

Neha Bajaj

Twinkle Trehan

Sathish Thirunavukkarasu

Affiliations

Soon will be listed here.

Abstract

Background: COVID-19, an infectious disease pandemic, affected millions of people globally, resulting in high morbidity and mortality. Causing further concern, significant proportions of COVID-19 survivors endure the lingering health effects of SARS-CoV-2, the pathogen that causes COVID-19. One of the diseases manifesting as a postacute sequela of COVID-19 (also known as "long COVID") is new-onset diabetes.

Objective: The aim of this study is to examine the incidence of new-onset diabetes in patients with long COVID and assess the excess risk compared with individuals who tested negative for COVID-19. The study also aims to estimate the population-attributable fraction for COVID-19 as a risk factor for new-onset diabetes in long COVID and investigate the clinical course of new-onset diabetes cases.

Methods: This is a protocol for a systematic review and meta-analysis. PubMed, MEDLINE, Embase, Scopus, and Web of Science databases will be systematically searched to identify articles published between December 2019 and July 2024. A comprehensive search strategy for each database will be developed using a combination of Medical Subject Headings terms, subject headings, and text words to identify eligible studies. Cohort studies and randomized controlled trials (only control arms) involving patients with COVID-19 of any age, with follow-up data on new-onset diabetes in long COVID, will be considered for inclusion. Controls will comprise individuals who tested negative for COVID-19, with or without other respiratory tract infections. Three independent reviewers (AST, NB, and TT) will perform article selection, data extraction, and quality assessment of the studies. A fourth reviewer (ST) will review the identified studies for final inclusion in the analysis. The random-effects DerSimonian-Laird models will be used to estimate the pooled incidence proportion (%), incidence rate of diabetes (per 1000 person-years), and risk ratio (with 95% CIs) for diabetes incidence.

Results: A total of 1972 articles were identified through the initial search conducted in August 2023. After excluding duplicates, conducting title and abstract screening, and completing full-text reviews, 41 articles were found to be eligible for inclusion. The search will be updated in July 2024. Currently, data extraction is underway, and the meta-analysis is expected to be completed in August 2024. Publication of the study findings is anticipated by the end of 2024.

Conclusions: The study findings should provide valuable insights to inform both clinical practice and public health policies regarding the effective management of new-onset diabetes in patients with long COVID.

International Registered Report Identifier (irrid): DERR1-10.2196/54853.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

Sathish T, Cao Y, Kapoor N . Newly diagnosed diabetes in COVID-19 patients. Prim Care Diabetes. 2020; 15(1):194. PMC: 7451214. DOI: 10.1016/j.pcd.2020.08.014. View

Harding J, Oviedo S, Ali M, Ofotokun I, Gander J, Patel S . The bidirectional association between diabetes and long-COVID-19 - A systematic review. Diabetes Res Clin Pract. 2022; 195:110202. PMC: 9727969. DOI: 10.1016/j.diabres.2022.110202. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Chen C, Haupert S, Zimmermann L, Shi X, Fritsche L, Mukherjee B . Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022; 226(9):1593-1607. PMC: 9047189. DOI: 10.1093/infdis/jiac136. View

Banerjee M, Pal R, Dutta S . Risk of incident diabetes post-COVID-19: A systematic review and meta-analysis. Prim Care Diabetes. 2022; 16(4):591-593. PMC: 9148988. DOI: 10.1016/j.pcd.2022.05.009. View

. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2023; 47(Suppl 1):S20-S42. PMC: 10725812. DOI: 10.2337/dc24-S002. View

10.

Lin L, Chu H . Quantifying publication bias in meta-analysis. Biometrics. 2017; 74(3):785-794. PMC: 5953768. DOI: 10.1111/biom.12817. View

11.

Ssentongo P, Zhang Y, Witmer L, Chinchilli V, Ba D . Association of COVID-19 with diabetes: a systematic review and meta-analysis. Sci Rep. 2022; 12(1):20191. PMC: 9684130. DOI: 10.1038/s41598-022-24185-7. View

12.

Kim Y, Bae S, Chang H, Kim S . Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. Sci Rep. 2023; 13(1):11207. PMC: 10336045. DOI: 10.1038/s41598-023-36995-4. View

13.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

14.

Sathish T . Risk of mortality in COVID-19 patients with newly diagnosed and pre-existing diabetes. Prim Care Diabetes. 2022; 16(1):214. PMC: 8695123. DOI: 10.1016/j.pcd.2021.12.002. View

15.

Luchini C, Veronese N, Nottegar A, Shin J, Gentile G, Granziol U . Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools. Pharm Stat. 2020; 20(1):185-195. DOI: 10.1002/pst.2068. View

16.

Sathish T, Anton M . Newly diagnosed diabetes in patients with mild to moderate COVID-19. Diabetes Metab Syndr. 2021; 15(2):569-571. PMC: 7925231. DOI: 10.1016/j.dsx.2021.02.034. View

17.

Zhang T, Mei Q, Zhang Z, Walline J, Liu Y, Zhu H . Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med. 2022; 20(1):444. PMC: 9666960. DOI: 10.1186/s12916-022-02656-y. View

18.

Sathish T, Anton M, Sivakumar T . New-onset diabetes in "long COVID". J Diabetes. 2021; 13(8):693-694. PMC: 8251301. DOI: 10.1111/1753-0407.13187. View

19.

. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023; 402(10397):203-234. PMC: 10364581. DOI: 10.1016/S0140-6736(23)01301-6. View

20.

Bellia C, Andreadi A, DIppolito I, Scola L, Barraco S, Meloni M . Prevalence and risk of new-onset diabetes mellitus after COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023; 14:1215879. PMC: 10507325. DOI: 10.3389/fendo.2023.1215879. View